Got $1,000? 2 No-Brainer Nuclear Stocks to Buy Right Now.

Oklo offers a high-risk advanced-reactor growth case, with analysts implying up to 230% 12-month upside, but it remains effectively pre-revenue: Q2 revenue was $1.21 million against $74 million of operating expenses, while its planned 1.2GW Ohio campus is intended to support Meta. Cameco offers a more established nuclear exposure, with contracted uranium deliveries averaging more than 28 million pounds annually from 2026-2030 and C$676 million ($483 million) of first-half 2026 uranium adjusted EBITDA. Analysts rate Cameco a strong buy with up to 55% projected upside, versus a moderate-buy rating for Oklo, framing Cameco as the steadier choice and Oklo as the higher-upside speculative option.

Analysis

The investable bottleneck is not reactor demand but bankable execution: fuel qualification, NRC licensing milestones, EPC cost control, and creditworthy offtake. OKLO’s valuation will remain disproportionately sensitive to each permitting or customer-contract headline because its cash needs arrive well before operating cash flow; a large hyperscaler relationship only deserves valuation credit once it includes binding capacity, price, delivery-date, and termination terms. HALEU availability is an underappreciated constraint for advanced-reactor developers, creating potential second-order beneficiaries in enrichment and fuel-cycle capacity rather than reactor developers alone.

CCJ/CCO offers a different earnings mechanism: contracted uranium volumes and the Westinghouse stake can reduce dependence on spot uranium, but also limit upside relative to a pure uranium beta if spot prices spike. The more compelling structural read-through is that nuclear life-extension, fuel fabrication, and reactor services monetize earlier than new-build deployment; BWXT and LEU may capture portions of the same spending cycle with materially shorter revenue lead times. Over the next 1-3 months, uranium-price direction and utility contracting activity matter more for CCJ than data-center power headlines; over 6-18 months, advanced-reactor licensing and fuel supply determine whether OKLO’s optionality converts into an asset value.

Consensus appears to treat data-center electricity demand as interchangeable with nuclear demand. In reality, hyperscalers can bridge near-term load growth through gas, grid interconnection, renewables-plus-storage, and conventional nuclear PPAs, making first-of-a-kind SMR delivery dates—not demand—the key equity variable. A delay in commercial operation, a revised capital estimate, or an equity raise would compress OKLO’s long-duration multiple quickly, while CCJ is more vulnerable to uranium price retracement, contract repricing, and Kazakh supply normalization.

Key Decisions for Investors

• Prefer CCJ (or CCO.TO) over OKLO on a 6-18 month horizon; size as a core nuclear allocation rather than a momentum trade. The thesis is falsified by a sustained uranium-price decline combined with weaker contracting/volume guidance or a material deterioration in Westinghouse distributions.
• Establish a risk-defined pair: long CCJ / short OKLO, initiated only after confirming comparable beta-adjusted exposure and borrow availability; target a 3-6 month holding period. It monetizes the execution-versus-demand distinction, with risk limits triggered by a binding, financeable OKLO power purchase agreement plus a credible construction schedule, or by a sharp uranium-price selloff.
• Maintain a watchlist rather than a position in OKLO until disclosure clarifies committed customer capacity, fuel sourcing, expected project capex, and financing structure. A documented fixed-price offtake and non-dilutive project financing would be the catalyst to replace the short leg with upside call exposure.
• For earlier-cycle nuclear spending exposure, screen BWXT and LEU against CCJ after earnings for order backlog, HALEU capacity commitments, and margin guidance. Favor the name with verified backlog conversion rather than relying on announced reactor-campus capacity.